Hi Kdwc,
It’s been on hold a long time this trial with the Delta outbreak in India. They are obviously recovered to a point of functioning again on this one. Staff members becoming infected etc also. Never a good scenario, but vaccinations are making a difference.
I never doubted this wouldn’t go ahead & we have the Lead Investigator on Janssen’s (J&J) CREDENCE study that was groundbreaking in Diabetic Kidney Disease & Chronic Kidney Disease as a Lead Investigator on this Study also (which really is an extension on an existing ARB study (Telmisartan) but this one we will be using Candisartan + DMX-200).
I have no idea of what the Market thinks, but I agree that some may have sold some to fund SPP. Onwards & upwards.
Ph3 trials, & as much as we have some expensive monoclonal antibodies to treat patients early with COVID-19, even here in Australia they are limited to the most high risk patients on risk criteria. A few pills to keep patients out of hospital is far preferable.
- Forums
- ASX - By Stock
- Ann: DMX-200 CLARITY COVID-19 Study Approval in India
Hi Kdwc,It’s been on hold a long time this trial with the Delta...
-
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
|
|||||
Last
40.0¢ |
Change
-0.010(2.44%) |
Mkt cap ! $220.2M |
Open | High | Low | Value | Volume |
41.5¢ | 42.0¢ | 39.5¢ | $839.4K | 2.070M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 35000 | 39.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
40.0¢ | 83901 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 0.395 |
4 | 60000 | 0.390 |
7 | 171788 | 0.385 |
8 | 327657 | 0.380 |
4 | 209342 | 0.375 |
Price($) | Vol. | No. |
---|---|---|
0.400 | 9924 | 2 |
0.410 | 103132 | 2 |
0.415 | 132474 | 5 |
0.420 | 108356 | 2 |
0.425 | 60000 | 2 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |